# Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for Hypertension

Study · id `cardio:ct-nct01520285` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01520285](<https://clinicaltrials.gov/study/NCT01520285>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01520285

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 281 participants.

## Technical summary

Registry record NCT01520285. Randomized; no masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2013-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 281 participants (enrolled count; ClinicalTrials.gov record NCT01520285, source copy `cardio:ctgov-nct01520285-2014-10-16`, retrieved 2026-10-26)
- Start date: 2011-12 (registry gives no type) (ClinicalTrials.gov record NCT01520285, source copy `cardio:ctgov-nct01520285-2014-10-16`, retrieved 2026-10-26)
- Primary completion: 2013-03 (actual) (ClinicalTrials.gov record NCT01520285, source copy `cardio:ctgov-nct01520285-2014-10-16`, retrieved 2026-10-26)
- Completion: 2013-08 (actual) (ClinicalTrials.gov record NCT01520285, source copy `cardio:ctgov-nct01520285-2014-10-16`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01520285, source copy `cardio:ctgov-nct01520285-2014-10-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01520285-2014-10-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for Hypertension
- Acronym: Zanidip
- Condition: Hypertension
- Intervention (Drug): Zanidip
- Intervention (Drug): Felodipine sustained-release tablet
- Lead sponsor: Lee's Pharmaceutical Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Lee's Pharmaceutical Limited (`cardio:org-lee-s-pharmaceutical-limited`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of lercanidipine hydrochloride versus felodipine sustained-release on day-to-day home blood pressure variability (`cardio:pubmed-27779454`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f76387d1492877f842c01b38dfb25c578807fd05ce8209a3dc53ae5d9da0beb5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
